Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

Intellia Therapeutics (NTLA) shares fell sharply after reporting a grade 4 liver transaminase elevation in a single, asymptomatic patient during its Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) for transthyretin amyloidosis with cardiomyopathy; however, the company indicated the elevation is resolving without intervention. Intellia anticipates completing enrollment in the MAGNITUDE study by early 2027 and remains on track with its NTLA-2002 program for hereditary angioedema, targeting a BLA submission in late 2026 and a potential U.S. launch in 2027.

Analysis

Intellia Therapeutics (NTLA) experienced a significant setback with its lead candidate, nexiguran ziclumeran (nex-z, NTLA-2001), after reporting a single, recent, asymptomatic patient in its Phase 3 MAGNITUDE study for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) developed grade 4 liver transaminase elevations. This event triggered a sharp 22.6% premarket decline in NTLA stock to $7.48. While Intellia noted these elevations are resolving without medical intervention and have decreased to grade 3 ALT and grade 2 AST, and that adverse events including asymptomatic liver transaminase elevations were observed in the Phase 1 study, the occurrence of a severe (grade 4) event in a pivotal trial raises safety concerns. The MAGNITUDE study has enrolled approximately 365 of an expected 765 patients, with over 200 dosed, and aims for full enrollment by early 2027. While Intellia detailed this single recent event, analyst firm William Blair commented on 'the two reported grade 4 LFT events with nex-z,' stating they remain positive on the risk/benefit profile as these events have been asymptomatic, avoided hospitalization, and are likely to resolve without medication. In contrast, HC Wainwright reiterated a Buy rating with a $30 price target, suggesting underlying confidence despite the safety signal. Intellia also reported that its global Phase 3 HAELO study for NTLA-2002 in hereditary angioedema (HAE) remains on track, with enrollment completion expected in Q3 2025, a BLA submission targeted for late 2026, and a potential U.S. launch in 2027. The Phase 3 MAGNITUDE-2 study of nex-z for ATTRv-PN is also progressing, targeting completion by 2028.

Key Decisions for Investors

• Investors should closely monitor future safety disclosures from the MAGNITUDE trial, as the nex-z liver toxicity signal represents a significant development risk despite the company's mitigating statements and some analyst optimism.
• The sharp stock decline warrants a re-evaluation of NTLA, weighing the increased risk for the ATTR-CM program against the maintained $30 price target from HC Wainwright and the unimpacted progress of the NTLA-2002 HAE program, which targets a BLA submission in late 2026.
• Consider the potential for ongoing share price volatility and the importance of the NTLA-2002 HAE program, with its targeted 2027 U.S. launch, as a key value driver that could partially offset challenges with nex-z.